Skip to main content
. 2021 Jun 21;11:694941. doi: 10.3389/fonc.2021.694941

Figure 3.

Figure 3

IHC staining of the tumor and clinical response in patient 2. (A) Anti-EphA2 IHC staining of tumor tissue before enrollment. (B) Expansion of CAR T-cells in the peripheral blood by flow cytometry (left y-axis) and qPCR (right y-axis). (C) Dynamic changes of critical cytokines in the peripheral blood along with temperature, after the infusion of CAR T-cells. (D) Contrast-enhanced brain MRI performed before and 4 weeks,12 weeks after the infusion of CAR T-cells.